Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use GLYRX®-PF safely and effectively. See full prescribing information for GLYRX®-PF.GLYRX®-PF (glycopyrrolate injection), for intravenous or intramuscular useInitial U.S. Approval: 1975
Medication labelWhy this: Advisory · dailymed-prescription
GLYRX®-PF is indicated: in anesthesia (all ages) •for reduction of salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation, •intraoperatively to counteract surgically or drug-induced or vagal reflex-associated arrhythmias, and •for protection against peripheral muscarinic effects of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing agents. in peptic ulcer (adults) •To reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. • Limitations of Use GLYRX-PF is not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.
- generic_name
- glycopyrrolate
- product_names
- glycopyrrolate
- ndc
- 51754-6015, 51754-6000, 51754-6001, 51754-6013, 51754-6015-3, 51754-6000-4, 51754-6001-4, 51754-6013-3
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en